Aspiriant LLC’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $764K | Buy |
1,524
+312
| +26% | +$150K | 0.02% | 200 |
|
|
2026
Q1 | $596K | Sell |
1,212
-198
| -14% | -$107K | 0.02% | 197 |
|
|
2025
Q4 | $817K | Sell |
1,410
-207
| -13% | -$117K | 0.02% | 171 |
|
|
2025
Q3 | $784K | Sell |
1,617
-11
| -0.7% | -$5.12K | 0.02% | 167 |
|
|
2025
Q2 | $660K | Sell |
1,628
-63
| -4% | -$26.3K | 0.02% | 177 |
|
|
2025
Q1 | $841K | Buy |
1,691
+23
| +1% | +$12.5K | 0.03% | 150 |
|
|
2024
Q4 | $868K | Buy |
1,668
+43
| +3% | +$23.6K | 0.03% | 151 |
|
|
2024
Q3 | $1.01M | Buy |
1,625
+154
| +10% | +$91.2K | 0.04% | 144 |
|
|
2024
Q2 | $813K | Sell |
1,471
-354
| -19% | -$203K | 0.03% | 156 |
|
|
2024
Q1 | $1.06M | Sell |
1,825
-17
| -0.9% | -$9.54K | 0.04% | 142 |
|
|
2023
Q4 | $978K | Sell |
1,842
-173
| -9% | -$83.7K | 0.04% | 147 |
|
|
2023
Q3 | $1.02M | Buy |
2,015
+179
| +10% | +$95.4K | 0.05% | 132 |
|
|
2023
Q2 | $958K | Buy |
1,836
+1
| +0.1% | +$540 | 0.05% | 139 |
|
|
2023
Q1 | $1.06M | Sell |
1,835
-25
| -1% | -$14.1K | 0.06% | 128 |
|
|
2022
Q4 | $1.02M | Buy |
1,860
+276
| +17% | +$146K | 0.05% | 130 |
|
|
2022
Q3 | $805K | Buy |
1,584
+101
| +7% | +$56.5K | 0.04% | 132 |
|
|
2022
Q2 | $805K | Buy |
1,483
+16
| +1% | +$8.81K | 0.04% | 137 |
|
|
2022
Q1 | $866K | Sell |
1,467
-42
| -3% | -$24.1K | 0.05% | 143 |
|
|
2021
Q4 | $1.01M | Buy |
1,509
+22
| +1% | +$13.7K | 0.05% | 132 |
|
|
2021
Q3 | $849K | Sell |
1,487
-72
| -5% | -$39.5K | 0.05% | 127 |
|
|
2021
Q2 | $786K | Sell |
1,559
-52
| -3% | -$24.5K | 0.04% | 131 |
|
|
2021
Q1 | $735K | Buy |
1,611
+19
| +1% | +$9.07K | 0.05% | 124 |
|
|
2020
Q4 | $741K | Buy |
1,592
+54
| +4% | +$25.3K | 0.05% | 124 |
|
|
2020
Q3 | $681K | Buy |
1,538
+8
| +0.5% | +$3.31K | 0.05% | 130 |
|
|
2020
Q2 | $554K | Buy |
+1,530
| New | +$513K | 0.05% | 125 |
|
|
2019
Q3 | – | Sell |
-745
| Closed | -$219K | – | 229 |
|
|
2019
Q2 | $219K | Hold |
745
| – | – | 0.02% | 210 |
|
|
2019
Q1 | $204K | Sell |
745
-264
| -26% | -$65.7K | 0.02% | 220 |
|
|
2018
Q4 | $225K | Buy |
+1,009
| New | +$237K | 0.02% | 211 |
|
|
2018
Q2 | – | Sell |
-992
| Closed | -$205K | – | 262 |
|
|
2018
Q1 | $205K | Buy |
+992
| New | +$208K | 0.02% | 229 |
|
Other funds holding TMO
Aspiriant LLC's TMO Position: Q2 2026 in Review
Aspiriant LLC increased its Thermo Fisher Scientific (TMO) stake by 26% in Q2 2026, buying an estimated $150K and bringing the position to 1,524 shares worth $764K. The position accounts for 0.02% of the portfolio, ranked #200.
Aspiriant LLC first reported a position in TMO in Q1 2018 and has held it in 29 quarters since. The position peaked at $1.06M in Q1 2024. 2,619 funds tracked by Wall St. Rank hold TMO as of Q2 2026.
- Aspiriant LLC held 1,524 shares of Thermo Fisher Scientific worth $764K as of Q2 2026.
- Aspiriant LLC bought 312 Thermo Fisher Scientific shares in Q2 2026, an estimated $150K.
- Thermo Fisher Scientific made up 0.02% of Aspiriant LLC's portfolio in Q2 2026, its #200 holding.
- Aspiriant LLC first reported a position in Thermo Fisher Scientific in Q1 2018 and has held it in 29 quarters since.
- Aspiriant LLC's Thermo Fisher Scientific position peaked at $1.06M in Q1 2024.
- 2,619 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.
Based on Aspiriant LLC's 13F filing for Q2 2026, filed 20 Jul 2026.